The systematic study of pyrimidines began in 1884 with Pinner, who synthesized derivatives by condensing ethyl acetoacetate with amidines. Pinner first proposed the name “pyrimidin” in 1885. 2927-71-1, formula is C4HCl2FN2, Name is 2,4-Dichloro-5-fluoropyrimidine. The parent compound was first prepared by Gabriel and Colman in 1900, by conversion of barbituric acid to 2,4,6-trichloropyrimidine followed by reduction using zinc dust in hot water. Reference of 2927-71-1.
Wu, Bin;Yang, Song;Deng, Tuo;Wang, Changyuan;Jin, Yue;Yu, Jiawen;Xu, Youjun;Chen, Lixue;Li, Yanxia;Ma, Xiaodong research published 《 Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma》, the research content is summarized as follows. A series of cyano-substituted 2,4-diarylaminopyrimidines I [X = F, Cl, CF3; R1 = 4-ethylpiperazin-1-yl, 2-ethyl-5-methyl-imidazol-1-ylmethyl; R2 = 2-CN, 3-CN, 4-CN] were designed and synthesized as potent non-covalent JAK3 inhibitors. Among the derivatives synthesized, I [X = Cl; R1 = 4-ethylpiperazin-1-yl, 2-morpholinoacetylamino; R2 = 2-CN, 3-CN, 4-CN] (IC50 = 22.86 nM), (IC50 = 21.58 nM), and (IC50 = 20.66 nM) demonstrated inhibitory potencies against JAK3 similar to the known JAK3 inhibitor tofacitinib (IC50 = 20.10 nM). Moreover, comp. I [X = Cl; R1 = 4-ethylpiperazin-1-yl; R2 = 4-CN] displayed potent anti-proliferative activities against Raji and Ramos cells, with IC50 values of 0.9255 μM and 1.405 μM,resp. In addition, comp. I [X = Cl; R1 = 4-ethylpiperazin-1-yl; R2 = 4-CN] demonstrated low toxicity in normal HBE (human bronchial epithelial cells, IC50 > 10 μΜ) and L-02 (human liver cells, IC50 = 3.104 μΜ) cells. Anal. of the mode of action by flow cytometry indicated that comp. I [X = Cl; R1 = 4-ethylpiperazin-1-yl; R2 = 4-CN] effectively arrested Raji cells at the G2/M phase. Taken together, these results suggested that comp. I [X = Cl; R1 = 4-ethylpiperazin-1-yl; R2 = 4-CN] was a promising candidate for development as a potential treatment for B-cell lymphoma.
2927-71-1, 2,4-Dichloro-5-fluoropyrimidine is a useful research compound. Its molecular formula is C4HCl2FN2 and its molecular weight is 166.97 g/mol. The purity is usually 95%.
2,4-Dichloro-5-fluoropyrimidine is an aromatic hydrocarbon that has been shown to inhibit the growth of mouse tumor cells in vitro. It also inhibits the production of amines by reacting with industrial chemicals and sodium carbonate. This compound has potent inhibitory activity against autoimmune diseases and cytotoxic potency on mcf-7 cells. Furthermore, 2,4-Dichloro-5-fluoropyrimidine has been shown to have a chlorinating effect on cancer cells., Reference of 2927-71-1
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia